FMO1

Summary

FMO1 (flavin containing dimethylaniline monoxygenase 1, HGNC:3769) is a protein-coding gene on chromosome 1q24.3, encoding Flavin-containing monooxygenase 1 (Q01740). Broad spectrum monooxygenase that catalyzes the oxygenation of a wide variety of nitrogen- and sulfur-containing compounds including xenobiotics.

Metabolic N-oxidation of the diet-derived amino-trimethylamine (TMA) is mediated by flavin-containing monooxygenase and is subject to an inherited FMO3 polymorphism in man resulting in a small subpopulation with reduced TMA N-oxidation capacity resulting in fish odor syndrome Trimethylaminuria. Three forms of the enzyme, FMO1 found in fetal liver, FMO2 found in adult liver, and FMO3 are encoded by genes clustered in the 1q23-q25 region. Flavin-containing monooxygenases are NADPH-dependent flavoenzymes that catalyzes the oxidation of soft nucleophilic heteroatom centers in drugs, pesticides, and xenobiotics. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 2326 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 79 total
• Druggable target: yes
• MANE Select transcript: NM_001282693

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3769
Approved symbol	FMO1
Name	flavin containing dimethylaniline monoxygenase 1
Location	1q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000010932
Ensembl biotype	protein_coding
OMIM	136130
Entrez	2326

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000354841, ENST00000367750, ENST00000402921, ENST00000459868, ENST00000469112, ENST00000469711, ENST00000472893, ENST00000617670

RefSeq mRNA: 4 — MANE Select: NM_001282693 NM_001282692, NM_001282693, NM_001282694, NM_002021

CCDS: CCDS1294, CCDS60351

Canonical transcript exons

ENST00000617670 — 9 exons

Exon	Start	End
ENSE00000789743	171281978	171282333
ENSE00000789744	171283144	171283216
ENSE00001620176	171248494	171248623
ENSE00003490304	171267543	171267731
ENSE00003502192	171275346	171275508
ENSE00003541211	171280786	171280985
ENSE00003666757	171278729	171278871
ENSE00003802426	171258082	171258219
ENSE00003807972	171285202	171285961

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 95.69.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.5597 / max 118.8361, expressed in 141 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6598	0.2327	29
6602	0.1731	74
6601	0.0893	52
6599	0.0645	17

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	95.69	gold quality
kidney epithelium	UBERON:0004819	95.03	gold quality
renal glomerulus	UBERON:0000074	93.57	gold quality
adult mammalian kidney	UBERON:0000082	92.70	gold quality
metanephric glomerulus	UBERON:0004736	92.59	gold quality
adult organism	UBERON:0007023	92.07	gold quality
kidney	UBERON:0002113	90.08	gold quality
ileal mucosa	UBERON:0000331	89.87	gold quality
parietal pleura	UBERON:0002400	89.57	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.96	gold quality
cortex of kidney	UBERON:0001225	85.04	gold quality
pleura	UBERON:0000977	82.72	gold quality
renal medulla	UBERON:0000362	81.28	gold quality
metanephros	UBERON:0000081	81.25	gold quality
oral cavity	UBERON:0000167	80.74	gold quality
upper leg skin	UBERON:0004262	80.08	gold quality
right adrenal gland cortex	UBERON:0035827	79.99	gold quality
skin of hip	UBERON:0001554	79.97	gold quality
thoracic mammary gland	UBERON:0005200	77.80	gold quality
right adrenal gland	UBERON:0001233	77.72	gold quality
mammary gland	UBERON:0001911	77.42	gold quality
gall bladder	UBERON:0002110	77.23	gold quality
mammary duct	UBERON:0001765	77.17	gold quality
left uterine tube	UBERON:0001303	76.92	gold quality
epithelium of mammary gland	UBERON:0003244	76.47	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.08	gold quality
left adrenal gland cortex	UBERON:0035825	75.99	gold quality
left adrenal gland	UBERON:0001234	75.92	gold quality
right ovary	UBERON:0002118	75.75	gold quality
skin of abdomen	UBERON:0001416	75.55	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	35.14
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI1, HNF4A

miRNA regulators (miRDB)

30 targeting FMO1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-3916	98.99	68.04	2155
HSA-MIR-6871-5P	98.90	66.67	671
HSA-MIR-3611	98.76	68.76	1290
HSA-MIR-1537-5P	98.70	68.33	999
HSA-MIR-548AO-5P	98.55	69.57	1362
HSA-MIR-548AX	98.55	69.58	1362
HSA-MIR-193B-5P	97.91	65.88	837
HSA-MIR-3936	97.64	64.47	732
HSA-MIR-4676-5P	97.54	65.29	715
HSA-MIR-575	97.54	65.18	718
HSA-MIR-101-5P	96.84	65.66	649
HSA-MIR-3059-3P	96.71	67.08	606
HSA-MIR-1251-5P	95.78	64.10	374

Literature-anchored findings (GeneRIF, showing 15)

• FMO1 expression is restricted to the fetus; FMO1 suppression occurred within 3 d postpartum in a process tightly coupled to birth, but not gestational age. (PMID:11809920)
• data from transient expression assays in HepG2 cells suggested this SNP could account for a 2- to 3-fold loss of FMO1 promoter activity. (PMID:12829732)
• “…in fetal liver, where FMO1 predominates attaining expression levels of (about) 32% of expressed CYP3A4.” p. 574 “…recent examples indicate that FMOs play a prominent role in the metabolism …of important drugs.” p. 575 (PMID:15203093)
• FMO1 was found to be down-regulated in human adult brain tissue. (PMID:16183778)
• Early studies described in this review document that FMO1 is the most abundant FMO enzyme in the human fetal liver, whereas FMO3 is essentially absent. (PMID:16863467)
• Specific allelic variants of the FMO1 gene might be associated to susceptibility to develop ALS. (PMID:17127561)
• The resulting data showed that N,N-dimethylamphetamine N-oxidation is mainly mediated by FMO1. (PMID:19552509)
• The results of this study suggested that the alteration of FMO gene expression is a consequence of the pathological environment linked to oxidative stress related to mutated SOD1. (PMID:21082301)
• polymorphisms in FMO1 are significant risk factors in the development of nicotine dependence and that the mechanism may involve variation in nicotine pharmacology. (PMID:21540762)
• data support the role of FMO3 in the N-oxidation of OLA and implicate for the first time the contribution of FMO1 and its functional *6 variant in OLA disposition (PMID:23147717)
• Report developmental regulation of hepatic FMO1 expression. (PMID:26839369)
• Study tested the genetic effects of three FMOs genes (FMO1, FMO3, and FMO6P) on nicotine dependence by performing targeted sequencing on 2,852 nicotine-dependent and nondependent smokers; identified significant association signals for gene FMO1 and FMO6P (PMID:28413702)
• Differential gene expression by SFRP2(+), FMO1(+), and COL11A1(+) fibroblasts suggests roles in matrix deposition, inflammatory cell retention, and connective tissue cell differentiation, respectively. (PMID:29080679)
• Decreases in N’-oxidation activity (V (max)/K (m)) were observed for the FMO1(I303V), FMO3(N61S), FMO3(D132H), FMO3(V257M), and FMO3(E308G) variants in vitro when compared with their respective wild-type isoforms. (PMID:30381441)
• Human flavin-containing monooxygenase 1 and its long-sought hydroperoxyflavin intermediate. (PMID:34509493)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fmo1	ENSMUSG00000040181
rattus_norvegicus	Fmo1	ENSRNOG00000034191
caenorhabditis_elegans		WBGENE00001476
caenorhabditis_elegans		WBGENE00001478
caenorhabditis_elegans		WBGENE00001480
caenorhabditis_elegans	C01H6.4	WBGENE00007254
caenorhabditis_elegans	C46H11.2	WBGENE00016728

Paralogs (5): FMO3 (ENSG00000007933), FMO4 (ENSG00000076258), FMO2 (ENSG00000094963), FOXRED2 (ENSG00000100350), FMO5 (ENSG00000131781)

Protein

Protein identifiers

Flavin-containing monooxygenase 1 — Q01740 (reviewed: Q01740)

Alternative names: Dimethylaniline monooxygenase [N-oxide-forming] 1, Dimethylaniline oxidase 1, Fetal hepatic flavin-containing monooxygenase 1, Trimethylamine monooxygenase

All UniProt accessions (2): Q01740, A0A1W2PNR8

UniProt curated annotations — full annotation on UniProt →

Function. Broad spectrum monooxygenase that catalyzes the oxygenation of a wide variety of nitrogen- and sulfur-containing compounds including xenobiotics. Catalyzes the S-oxygenation of hypotaurine to produce taurine, an organic osmolyte involved in cell volume regulation as well as a variety of cytoprotective and developmental processes. In vitro, catalyzes the N-oxygenation of trimethylamine (TMA) to produce trimethylamine N-oxide (TMAO) and could therefore participate to the detoxification of this compound that is generated by the action of gut microbiota from dietary precursors such as choline, choline containing compounds, betaine or L-carnitine.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed mainly in fetal and adult liver.

Similarity. Belongs to the FMO family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q01740-1	1	yes
Q01740-2	2

RefSeq proteins (4): NP_001269621, NP_001269622, NP_001269623, NP_002012 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000960	Flavin_mOase	Family
IPR002253	Flavin_mOase_1	Family
IPR020946	Flavin_mOase-like	Family
IPR036188	FAD/NAD-bd_sf	Homologous_superfamily
IPR050346	FMO-like	Family

Pfam: PF00743

Enzyme classification (BRENDA):

• EC 1.14.13.8 — flavin-containing monooxygenase (BRENDA: 30 organisms, 458 substrates, 77 inhibitors, 260 Km, 123 kcat entries)

Substrate kinetics (BRENDA)

72 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
METHIMAZOLE	0.007–0.5758	18
TAMOXIFEN	0.0013–0.121	15
INDOLE	0.005–0.9	13
BENZYDAMINE	0.0186–0.0659	11
ETHIONAMIDE	0.104–2.131	10
METHYL P-TOLYL SULFIDE	0.0048–10.2	10
FENTHION	0.145–0.351	9
MERCAPTOIMIDAZOLE	0.018–0.0527	9
NADPH	0.0031–0.132	9
TRIMETHYLAMINE	0.0015–0.58	9
SULINDAC SULFIDE	0.0101–0.0163	8
CHLORPROMAZINE	0.022–0.08	7
IMIPRAMINE	0.0047–0.02	7
L-METHIONINE	2.8–48	6
10-[(N,N-DIMETHYLAMINOOCTYL)-2-(TRIFLUOROMETHYL)	15–38	5

Catalyzed reactions (Rhea), 4 shown:

• N,N-dimethylaniline + NADPH + O2 + H(+) = N,N-dimethylaniline N-oxide + NADP(+) + H2O (RHEA:24468)
• trimethylamine + NADPH + O2 = trimethylamine N-oxide + NADP(+) + H2O (RHEA:31979)
• hypotaurine + NADPH + O2 + H(+) = taurine + NADP(+) + H2O (RHEA:69819)
• hypotaurine + NADH + O2 + H(+) = taurine + NAD(+) + H2O (RHEA:74111)

UniProt features (22 total): sequence variant 9, binding site 6, topological domain 2, initiator methionine 1, chain 1, modified residue 1, splice variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01740-F1	94.46	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 195–198; 9–13; 32; 40–41; 60–61; 61–62

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1614558	Degradation of cysteine and homocysteine
R-HSA-217271	FMO oxidises nucleophiles

MSigDB gene sets: 166 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GOBP_LIPID_MODIFICATION, REACTOME_BIOLOGICAL_OXIDATIONS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, GATA3_01, GOBP_SULFUR_COMPOUND_BIOSYNTHETIC_PROCESS

GO Biological Process (8): sulfur amino acid catabolic process (GO:0000098), obsolete organic acid metabolic process (GO:0006082), xenobiotic metabolic process (GO:0006805), toxin metabolic process (GO:0009404), response to lipopolysaccharide (GO:0032496), taurine biosynthetic process (GO:0042412), negative regulation of fatty acid oxidation (GO:0046322), energy homeostasis (GO:0097009)

GO Molecular Function (8): monooxygenase activity (GO:0004497), N,N-dimethylaniline monooxygenase activity (GO:0004499), trimethylamine monooxygenase activity (GO:0034899), hypotaurine monooxygenase activity (GO:0047822), flavin adenine dinucleotide binding (GO:0050660), NADP binding (GO:0050661), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): endoplasmic reticulum lumen (GO:0005788), endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Sulfur amino acid metabolism	1
Phase I - Functionalization of compounds	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	3
sulfur amino acid metabolic process	1
sulfur compound catabolic process	1
carboxylic acid catabolic process	1
metabolic process	1
cellular response to xenobiotic stimulus	1
secondary metabolic process	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
taurine metabolic process	1
alkanesulfonate biosynthetic process	1
fatty acid oxidation	1
negative regulation of fatty acid metabolic process	1
regulation of fatty acid oxidation	1
multicellular organismal-level homeostasis	1
oxidoreductase activity	1
nucleotide binding	1
anion binding	1
adenyl nucleotide binding	1
binding	1
catalytic activity	1
endoplasmic reticulum	1
intracellular organelle lumen	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1790 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FMO1	B4GALT4	O60513	458
FMO1	CDC40	O60508	456
FMO1	LSP1	P33241	433
FMO1	HMG20B	Q9P0W2	430
FMO1	DVL1	O14640	430
FMO1	ABCD2	Q9UBJ2	427
FMO1	CAPN2	P17655	404
FMO1	LARP4	Q71RC2	398
FMO1	ITSN2	Q9NZM3	395
FMO1	GRIA1	P42261	386
FMO1	UGT1A6	P19224	382
FMO1	FMR1	Q06787	382
FMO1	HNRNPA1	P09651	377
FMO1	LPIN1	Q14693	376
FMO1	CMTM6	Q9NX76	365

IntAct

21 interactions, top by confidence:

A	B	Type	Score
FMO1	CREB3	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	FMO1	psi-mi:“MI:0915”(physical association)	0.560
FMO1	GRINA	psi-mi:“MI:0915”(physical association)	0.560
FMO1	REEP4	psi-mi:“MI:0915”(physical association)	0.560
FMO1	SLC10A6	psi-mi:“MI:0915”(physical association)	0.560
FMO1	MFSD14B	psi-mi:“MI:0915”(physical association)	0.560
FMO1	TLN1	psi-mi:“MI:0407”(direct interaction)	0.440
FMO1	LDHC	psi-mi:“MI:0914”(association)	0.350
LEPROTL1	FMO1	psi-mi:“MI:0915”(physical association)	0.000
GRINA	FMO1	psi-mi:“MI:0915”(physical association)	0.000
FMO1	REEP4	psi-mi:“MI:0915”(physical association)	0.000
FMO1	MFSD14B	psi-mi:“MI:0915”(physical association)	0.000
FMO1	SLC10A6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): CREB3 (Two-hybrid), LEPROTL1 (Two-hybrid), SLC10A6 (Two-hybrid), HIATL1 (Two-hybrid), REEP4 (Two-hybrid), GRINA (Two-hybrid), GPRC5C (Affinity Capture-MS), FMO4 (Affinity Capture-MS), LDHC (Affinity Capture-MS), FMO1 (Negative Genetic), FMO1 (Protein-peptide), HSP90AB1 (Cross-Linking-MS (XL-MS)), FMO1 (Proximity Label-MS)

ESM2 similar proteins: A1E9I4, A1E9R7, A1EA01, A2T321, A6H5F6, A7M8Z3, A8W3H9, A8Y9G3, A9QC56, B0YPM1, B1VKH6, F4JIU4, O14977, O35484, O60774, P06354, P06360, P0C480, P0C481, P0C482, P16037, P17933, P41605, P51249, Q01740, Q06FX2, Q1ACN3, Q1XDN8, Q32RQ0, Q32RY1, Q569R5, Q5R7K3, Q5SCY1, Q63764, Q6ENI1, Q6ENX0, Q6KGX3, Q6L3A4, Q6YXJ9, Q85AW7

Diamond homologs: A0A0B5RNJ4, A3SLM3, A3VVZ4, B6BQB2, B8EIZ7, P16549, P49109, P49326, Q01740, Q04799, Q1V023, Q5LT63, Q8MP06, O23024, O60774, P17635, P31512, P36365, P36366, P36367, P50285, P97872, Q28505, Q5REK0, Q6IRI9, Q8HZ69, Q8HZ70, Q8K2I3, Q8K4C0, Q93Y23, Q99518, Q9C8U0, Q9FWW6, Q9SH25, Q9SS04, Q9SXD5, A0A0P0V5U9, A0A172J1R7, A3U3H1, B8ANW0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	6
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1593 predictions. Top by Δscore:

Variant	Effect	Δscore
1:171258220:G:GG	donor_gain	1.0000
1:171275341:TTCA:T	acceptor_loss	1.0000
1:171275342:TCA:T	acceptor_loss	1.0000
1:171275344:A:AG	acceptor_gain	1.0000
1:171275344:A:C	acceptor_loss	1.0000
1:171275345:G:GG	acceptor_gain	1.0000
1:171275345:GA:G	acceptor_gain	1.0000
1:171275345:GACC:G	acceptor_gain	1.0000
1:171275345:GACCA:G	acceptor_gain	1.0000
1:171275505:CCAG:C	donor_loss	1.0000
1:171278718:A:AG	acceptor_gain	1.0000
1:171278719:T:G	acceptor_gain	1.0000
1:171278724:TATAG:T	acceptor_gain	1.0000
1:171278725:A:AG	acceptor_gain	1.0000
1:171278725:ATAG:A	acceptor_gain	1.0000
1:171278725:ATAGG:A	acceptor_gain	1.0000
1:171278726:T:G	acceptor_gain	1.0000
1:171278726:TA:T	acceptor_loss	1.0000
1:171278726:TAG:T	acceptor_gain	1.0000
1:171278727:A:AG	acceptor_gain	1.0000
1:171278727:A:C	acceptor_loss	1.0000
1:171278727:AG:A	acceptor_gain	1.0000
1:171278727:AGGTA:A	acceptor_gain	1.0000
1:171278728:G:GC	acceptor_gain	1.0000
1:171278728:GG:G	acceptor_gain	1.0000
1:171278728:GGT:G	acceptor_gain	1.0000
1:171278728:GGTA:G	acceptor_gain	1.0000
1:171278728:GGTAT:G	acceptor_gain	1.0000
1:171278868:AAAG:A	donor_loss	1.0000
1:171278870:AG:A	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000024256 (1:171263734 G>C,T), RS1000268684 (1:171247516 G>A), RS1000421411 (1:171277849 A>T), RS1000451140 (1:171261600 T>G), RS1000473138 (1:171264569 C>T), RS1000506690 (1:171249009 T>C), RS1000529561 (1:171284322 A>C), RS1000554353 (1:171262233 G>A), RS1000581841 (1:171283968 T>C), RS1000665091 (1:171254297 G>A), RS1000684160 (1:171251480 T>C), RS1000753161 (1:171277478 A>G), RS1000790987 (1:171256752 A>C), RS1000882863 (1:171276650 G>C), RS1001159467 (1:171283489 G>A)

Disease associations

OMIM: gene MIM:136130 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001104_7	Sudden cardiac arrest	2.000000e-06
GCST004125_11	Type 2 diabetes (age of onset)	4.000000e-06
GCST009391_1545	Metabolite levels	2.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004278	sudden cardiac arrest
EFO:0010511	niacinamide measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3430872 (SINGLE PROTEIN), CHEMBL3542432 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

4 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10912675	Other	3	nicotine
rs12720462	Other	3	olanzapine
rs7877	Other	3	olanzapine
rs7877	Other	3	nicotine

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7877	FMO1	3	1.75	2	nicotine;olanzapine
rs10912675	FMO1	3	1.50	1	nicotine
rs12720462	FMO1	3	1.75	1	olanzapine
rs13376631	FMO1		0.00	0

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	5
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	3
Benzydamine	decreases reaction, increases chemical synthesis, increases oxidation	2
Chenodeoxycholic Acid	affects cotreatment, decreases expression	2
Deoxycholic Acid	affects cotreatment, decreases expression	2
Glycochenodeoxycholic Acid	decreases expression, affects cotreatment	2
Glycocholic Acid	affects cotreatment, decreases expression	2
Glycodeoxycholic Acid	affects cotreatment, decreases expression	2
Nickel	decreases expression	2
Triclosan	affects cotreatment, decreases expression, increases expression	2
Cyclosporine	affects cotreatment, decreases expression	2
bisphenol F	decreases expression, affects cotreatment	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt	affects cotreatment, decreases expression	1
bisphenol A	increases expression	1
potassium perchlorate	decreases expression	1
pyrithione zinc	increases expression	1
N-methyl-4-aminophenol	affects cotreatment, increases chemical synthesis, increases oxidation	1
bromoacetate	decreases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	decreases expression	1
4-aminophenol	increases metabolic processing, affects cotreatment, increases chemical synthesis	1
maleic acid	increases expression	1
4-fluoroaniline	affects cotreatment, increases chemical synthesis, increases metabolic processing	1
nefazodone	affects cotreatment, decreases expression	1
usnic acid	affects cotreatment, decreases expression	1
clozapine N-oxide	decreases reaction, increases chemical synthesis	1
4-fluoro-N-methylaniline	affects cotreatment, increases chemical synthesis, increases metabolic processing, increases oxidation	1

ChEMBL screening assays

4 unique, capped per target: 4 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3531401	ADMET	Drug metabolism assessed as human recombinant FMO1-mediated ER-879123 formation at 10 uM after 60 mins by LC-MS/MS method in presence of NADPH	A Baeyer-Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. — Drug Metab Dispos

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.